GT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.325 USD | +2.99% |
|
+0.76% | -56.54% |
| Mar. 26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 01 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.59M |
|---|---|---|---|---|---|
| Net income 2024 * | -17M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.75% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.99% | ||
| 1 week | +0.76% | ||
| Current month | +10.83% | ||
| 1 month | -16.88% | ||
| 3 months | -30.73% | ||
| 6 months | -52.84% | ||
| Current year | -56.54% |
1 week
3.10
3.48
1 month
2.954.25
Current year
2.957.94
1 year
2.9516.11
3 years
2.95591.99
5 years
2.95591.99
10 years
2.951 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 21-01-12 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 22-02-17 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 3.325 | +2.99% | 13,309 |
| 24-05-09 | 3.228 | +4.14% | 2,108 |
| 24-05-08 | 3.1 | -4.02% | 1,959 |
| 24-05-07 | 3.23 | +0.31% | 13,571 |
| 24-05-06 | 3.22 | -2.42% | 9,715 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotes
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patientâs own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.325
USD
Average target price
150
USD
Spread / Average Target
+4,411.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.54% | 4.59M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- GTBP Stock
